Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM) Research Center, Montréal, Québec, Canada.
Department of Medicine, McGill University Health Center, Montréal, Québec, Canada.
Atherosclerosis. 2019 Oct;289:73-84. doi: 10.1016/j.atherosclerosis.2019.08.010. Epub 2019 Aug 23.
MicroRNA (miR)-146 is a key regulator of inflammation, endothelial activation and atherosclerosis. This study sought to define its potential role for the modulation of ischemia-induced neovascularization in atherosclerotic conditions.
Next generation sequencing and qRT-PCR analyses were used to compare microRNA expression in the ischemic muscles of hypercholesterolemic ApoE-deficient (ApoE) mice vs. wild type mice, and in HUVECs exposed or not to oxLDL. Neovascularization was investigated in a mouse model of hindlimb ischemia and the functional activities of HUVECs and pro-angiogenic cells (PACs) were assessed in vitro.
We found that miR-146b (but not miR-146a) is significantly reduced in the ischemic muscles of ApoE mice, and in HUVECs exposed to oxLDL. Inhibition of miR-146b reduces angiogenesis in vitro, whereas forced expression of miR-146b rescues oxLDL-mediated impairment of endothelial cell proliferation and tube formation. Mechanistically, miR146b directly targets tumor necrosis factor-alpha (TNFa) Receptor Associated Factor 6 (TRAF6) to inhibit inflammation. We found that hypercholesterolemia and oxLDL exposure are associated with higher levels of TRAF6, and increased expression of TNFa. However, forced expression of miR-146b in high cholesterol conditions reduces the expression of these inflammatory factors. In vivo, intramuscular injection of miR-146b mimic reduces ischemic damages and restores blood flow recuperation and capillary density in the ischemic muscles of ApoE mice. Treatment with miR-146b also increases the number and functional activities of pro-angiogenic cells (PACs).
Hypercholesterolemia is associated with reduced expression of miR-146b, which increases TRAF6-dependent inflammation and is associated with poor neovascularization in response to ischemia. Forced expression of miR-146b using a miR mimic could constitute a novel therapeutic strategy to improve ischemia-induced neovascularization in atherosclerotic conditions.
微小 RNA(miR)-146 是炎症、内皮激活和动脉粥样硬化的关键调节因子。本研究旨在确定其在动脉粥样硬化条件下调节缺血诱导的新血管生成中的潜在作用。
使用下一代测序和 qRT-PCR 分析比较了高胆固醇血症 ApoE 缺陷(ApoE)小鼠与野生型小鼠缺血肌肉中的 miRNA 表达,以及暴露于 oxLDL 或未暴露于 oxLDL 的 HUVECs。在小鼠后肢缺血模型中研究了新血管生成,在体外评估了 HUVEC 和促血管生成细胞(PAC)的功能活性。
我们发现 miR-146b(而非 miR-146a)在 ApoE 小鼠的缺血肌肉中和暴露于 oxLDL 的 HUVECs 中显著降低。miR-146b 抑制可减少体外血管生成,而强制表达 miR-146b 可挽救 oxLDL 介导的内皮细胞增殖和管形成受损。在机制上,miR146b 直接靶向肿瘤坏死因子-α(TNFa)受体相关因子 6(TRAF6)以抑制炎症。我们发现,高胆固醇血症和 oxLDL 暴露与 TRAF6 水平升高和 TNFa 表达增加有关。然而,在高胆固醇条件下强制表达 miR-146b 可降低这些炎症因子的表达。在体内,肌肉内注射 miR-146b 模拟物可减少缺血损伤,并恢复 ApoE 小鼠缺血肌肉的血流恢复和毛细血管密度。miR-146b 治疗还增加了促血管生成细胞(PAC)的数量和功能活性。
高胆固醇血症与 miR-146b 表达降低有关,这增加了 TRAF6 依赖性炎症,并与缺血后新血管生成不良有关。使用 miR 模拟物强制表达 miR-146b 可能成为改善动脉粥样硬化条件下缺血诱导新血管生成的新治疗策略。